
About us

About us
Founded in 2021 and led by a team of veteran biotherapeutics developers and protein engineers, Engimmune couples AI-guided innovation and laboratory insights to unlock the therapeutic potential of soluble TCR engagers. The company’s foundational technology is based on inventions by Dr. Rodrigo Vazquez-Lombardi and Prof. Sai Reddy. Engimmune closed its seed financing round in May 2022, which was co-led by Pureos Bioventures and Novo Holdings, and has since established a robust and differentiated pipeline of soluble TCR therapeutics.
Team

Sébastien Lalevée, PhD
Principal Scientist Immunology

Qinmei Yang, PhD
Research Scientist Immunology

Joseph Taft, PhD
Senior Scientist
Protein Engineering

Roy Ehling, PhD
Research Scientist Protein Engineering

Jakub Kucharczyk, PhD
Research Scientist
Protein Engineering

Sarah Wehrle, PhD
Research Scientist Protein Biochemistry/CMC

Valentin Junet, PhD
Data Scientist

Beichen Gao, PhD
Data Scientist

Tamara Lichtenstein, MSc
Research Associate
Protein Engineering

Juliette Forster, MSc
Research Associate
Protein Engineering

Chiara Lamanna, MSc
Research Associate
Protein Engineering

Raphael Ruch, MSc
Research Associate
Protein Engineering

Marie-Charlotte Diringer, MSc
Research Associate Immunology

Joshua Kämpf, MSc
Research Associate Immunology

Maria Franceskin, MSc
Research Associate Immunology

Marcela Vaz, PhD
Laboratory Manager

Martón Horváth, MSc
Research Associate Protein Biochemistry/CMC

Camille Wagner, MSc
Research Associate Protein Biochemistry/CMC
Board of Directors
